Concise review: Injectable biomaterials for the treatment of myocardial infarction and peripheral artery disease: Translational challenges and progress

Stem Cells Translational Medicine

Volumn 3, Issue 9, 2014, Pages 1090-1099

  Ungerleider, Jessica L ^a   Christman, Karen L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biocompatible materials; Myocardial infarction; Peripheral arterial disease; Translational medical research

Indexed keywords

ALGINIC ACID; BIOMATERIAL; COLLAGEN; DALTEPARIN; FIBROBLAST GROWTH FACTOR 2; GELATIN; GELFOAM; GOLD NANOPARTICLE; HYALURONIC ACID; HYDROXYAPATITE; MATRIGEL; MICROSPHERE; NANOFIBER; PROTAMINE; SCATTER FACTOR; SOMATOMEDIN C; STROMELYSIN; VASCULOTROPIN; HYDROGEL;

ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CLINICAL TRIAL (TOPIC); EXTRACELLULAR MATRIX; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYDROGEL; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REGENERATIVE MEDICINE; THROMBOCYTE RICH PLASMA; UMBILICAL VEIN ENDOTHELIAL CELL; ADMINISTRATION AND DOSAGE; ANIMAL; BIOLOGICAL THERAPY; DRUG DELIVERY SYSTEM; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PROCEDURES;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL- AND TISSUE-BASED THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEL; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE;

EID: 84906871710     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0049     Document Type: Article

References (63)

1. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics-2013 Update: A report from the American Heart Association. Circulation 2013;127:e6-e245.
2. Ostchega Y, Paulose-Ram R, Dillon CF et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: Data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc 2007;55:583-589.
3. White CJ, Gray WA. Endovascular therapies for peripheral arterial disease: An evidence-based review. Circulation 2007;116: 2203-2215.
4. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: Microvascular therapies coming of age. Circulation 2008;118:9-16.
5. Christman KL, Fok HH, Sievers RE et al. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 2004;10: 403-409.
6. ChristmanKL, VardanianAJ, FangQet al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 2004;44:654-660.
7. Kofidis T, de Bruin JL, Hoyt G et al. Injectable bioartificial myocardial tissue for largescale intramural cell transfer and functional recovery of injured heartmuscle. J Thorac Cardiovasc Surg 2004;128:571-578.
8. Iwakura A, Fujita M, Kataoka K et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels 2003;18:93-99.
9. Rane AA, Christman KL. Biomaterials for the treatment of myocardial infarction: A 5-year update. J Am Coll Cardiol 2011;58:2615-2629.
10. Johnson TD, Christman KL. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction. Expert Opin Drug Deliv 2013;10:59-72.
11. Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol 2006;48:907-913.
12. Burdick JA, Mauck RL, Gorman JH et al. Acellular biomaterials: An evolving alternative to cell-based therapies. Sci Transl Med 2013; 5:176ps4.
13. NelsonDM, MaZ, Fujimoto KL et al. Intramyocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges. Acta Biomater 2011;7:1-15.
14. Segers VF, Lee RT. Biomaterials to enhance stem cell function in the heart. Circ Res 2011;109:910-922.
15. Lin YD, Yeh ML, Yang YJ et al. Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs. Circulation 2010;122(suppl):S132-S141.
16. Ladage D, Turnbull IC, Ishikawa K et al. Delivery of Gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther 2011; 18:979-985.
17. Liu Y, Sun L, Huan Y et al. Effects of basic fibroblast growth factor microspheres on angiogenesis in ischemic myocardium and cardiac function: Analysis with dobutamine cardiovascular magnetic resonance tagging. Eur J Cardiothorac Surg 2006;30:103-107.
18. Lin YD, Luo CY, Hu YN et al. Instructive nanofiber scaffolds withVEGFcreate a microenvironment for arteriogenesis and cardiac repair. Sci Transl Med 2012;4:146ra109.
19. Koudstaal S, Bastings MM, Feyen DA et al. Sustained delivery of insulin-like growth factor-1/hepatocyte growth factor stimulates endogenous cardiac repair in the chronic infarcted pig heart. J Cardiovasc Transl Res 2014;7:232-241.
20. Eckhouse SR, Purcell BP, McGarvey JR et al. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med 2014;6:223ra221.
21. Polizzotti BD, Arab S, Kühn B. Intrapericardial delivery of Gelfoamenables the targeted delivery of periostin peptide after myocardial infarction by inducing fibrin clot formation. PLoS One 2012;7:e36788.
22. Mukherjee R, Zavadzkas JA, SaundersSM et al. Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg 2008;86: 1268-1276.
23. Leor J, Tuvia S, Guetta V et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in swine. JAmColl Cardiol 2009;54:1014-1023.
24. Ikaria Holdings Inc. NCT01226563: IK-5001 for the prevention of remodeling of the ventricle and congestive heart failure after acute myocardial infarction (PRESERVATION 1). Available at http://www.clinicaltrials.gov/ show/NCT01226563. Accessed June 25, 2014.
25. BioLineRx Ltd. NCT00557531: Safety and feasibility of the injectable BL-1040 implant. Available at http://www.clinicaltrials.gov/show/ NCT00557531. Accessed June 25, 2014.
26. Ifkovits JL, Tous E, MinakawaM et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc Natl Acad Sci USA 2010;107:11507-11512.
27. Seif-Naraghi SB, Singelyn JM, Salvatore M et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med 2013;5:173ra25.
28. Tang ZC, Liao WY, Tang AC et al. The enhancement of endothelial cell therapy for angiogenesis in hindlimb ischemia using hyaluronan. Biomaterials 2011;32:75-86.
29. Wang J, Cui W, Ye J et al. A cellular delivery system fabricated with autologous BMSCs and collagen scaffold enhances angiogenesis and perfusion in ischemic hind limb. J Biomed Mater Res A 2012;100:1438-1447.
30. Mima Y, Fukumoto S, Koyama H et al. Enhancement of cell-based therapeutic angiogenesis using a novel type of injectable scaffolds of hydroxyapatite-polymer nanocomposite microspheres. PLoS One 2012;7:e35199.
31. Marui A, Tabata Y, Kojima S et al. A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained releaseof basic fibroblast growth factor usingbiodegradable gelatin hydrogel: An initial report of the phase I-IIa study. Circ J 2007;71:1181-1186.
32. Zhao Y, Liu Z, Pan C et al. Preparation of gelatin microspheres encapsulated with bFGF for therapeutic angiogenesis in a canine ischemic hind limb. J Biomater Sci Polym Ed 2011; 22:665-682.
33. Ruvinov E, Leor J, Cohen S. The effects of controlledHGFdelivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials 2010;31:4573-4582.
34. Kuraitis D, Zhang P, Zhang Y et al. A stromal cell-derived factor-1 releasing matrix enhances the progenitor cell response and blood vessel growth in ischaemic skeletal muscle. Eur Cell Mater 2011;22:109-123.
35. Nakamura S, Ishihara M, Takikawa M et al. Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery system. Tissue Eng Part A 2012;18:2239-2247.
36. Fujita M, Horio T, Kishimoto S et al. Effects of platelet-rich plasma-containing fragmin/protamine microparticles in enhancing endothelial and smooth muscle cell growth and inducing collateral vessels in a rabbit model of hindlimb ischemia. J Biomed Mater Res B Appl Biomater 2013;101:36-42.
37. Kim JH, Jung Y, Kim BS et al. Stem cell recruitment and angiogenesis of neuropeptide substance P coupled with self-assembling peptide nanofiber in a mouse hind limb ischemia model. Biomaterials 2013;34:1657-1668.
38. Webber MJ, Tongers J, NewcombCJ et al. Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair. Proc Natl Acad Sci USA 2011;108:13438-13443.
39. Kim J, Cao L, ShvartsmanDet al. Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett 2011;11:694-700.
40. Lee J, Bhang SH, ParkH et al. Active blood vessel formation in the ischemic hindlimb mouse model using a microsphere/hydrogel combination system. Pharm Res 2010;27: 767-774.
41. Xie J, Wang H, Wang Y et al. Induction of angiogenesis by controlled delivery of vascular endothelial growth factor using nanoparticles. Cardiovasc Ther 2013;31:e12-e18.
42. Fan CL, Gao PJ, Gu YJ et al. Therapeutic angiogenesis by intramuscular injection of fibrin particles into ischaemic hindlimbs. Clin Exp Pharmacol Physiol 2006;33:617-622.
43. DeQuachJA, Lin JE, CamC et al. Injectable skeletal muscle matrix hydrogel promotes neovascularization and muscle cell infiltration in a hindlimb ischemia model. Eur Cell Mater 2012;23:400-412.
44. LoneStar Heart Inc. NCT01311791: A randomized, controlled study to evaluate algisyl-LVR as a method of left ventricular augmentation for heart failure (AUGMENT-HF). Available at http://www.clinicaltrials.gov/ show/NCT01311791. Accessed June 25, 2014.
45. LoneStar Heart Inc. NCT00847964: Safety and feasibility of algisyl-LVR as a method of left ventricular restoration in patients withDCMundergoing open-heart surgery. Available at http:// www.clinicaltrials.gov/show/NCT00847964. Accessed June 25, 2014.
46. Lee RJ, Hinson A, Helgerson S et al. Polymer-based restoration of left ventricular mechanics. Cell Transplant 2013;22:529-533.
47. Ouma GO, Jonas RA, Usman MH et al. Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease. Vasc Med 2012;17:174-192.
48. U.S. Food and Drug Administration. Draft Guidance for Industry and FDA Staff: Classification of Products as Drugs and Devices and Additional Product Classification Issues. June 2011. Available at http://www.fda.gov/ downloads/RegulatoryInformation/Guidances/ UCM258957.pdf. Accessed June 25, 2014.
49. Pashuck ET, Stevens MM. Designing regenerative biomaterial therapies for the clinic. Sci Transl Med 2012;4:160sr4.
50. US Food and Drug Administration. Guidance for Industry: PreclinicalAssessmentof Investigational Cellular and Gene Therapy Products. Available at http://www.fda.gov/biologicsblood vaccines/guidancecomplianceregulatoryinfor mation/guidances/cellularandgenetherapy/ ucm376136.htm. Accessed June 25, 2014.
51. Kadner K, Dobner S, Franz T et al. The beneficial effects of deferred delivery on the efficiency of hydrogel therapy post myocardial infarction. Biomaterials 2012;33:2060-2066.
52. Hu X, Wang J, Chen J et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg 2007;31:438-443.
53. Agudelo CA, Tachibana Y, Hurtado AF et al. The use of magnetic resonance cell tracking to monitor endothelial progenitor cells in a rat hindlimb ischemic model. Biomaterials 2012;33:2439-2448.
54. Johnson TD, Dequach JA, Gaetani R et al. Human versus porcine tissue sourcing for an injectable myocardial matrix hydrogel. Biomater Sci 2014;2014:60283D.
55. Seif-Naraghi SB, Horn D, Schup-Magoffin PA et al. Patient-to-patient variability in autologous pericardial matrix scaffolds for cardiac repair. J Cardiovasc Transl Res 2011;4:545-556.
56. Sicari BM, Johnson SA, Siu BF et al. The effect of source animal age upon the in vivo remodeling characteristics of an extracellular matrix scaffold. Biomaterials 2012;33:5524-5533.
57. Tottey S, Johnson SA, CrapoPMet al. The effect of source animal age upon extracellular matrix scaffold properties. Biomaterials 2011; 32:128-136.
58. Abbasalizadeh S, Baharvand H. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol Adv 2013;31:1600-1623.
59. Giancola R, Bonfini T, Iacone A. Cell therapy: cGMP facilities and manufacturing. Muscles Ligaments Tendons J 2012;2:243-247.
60. Mayfield AE, Tilokee EL, Latham N et al. The effect of encapsulation of cardiac stem cells withinmatrix-enriched hydrogel capsules on cell survival, post-ischemic cell retention and cardiac function. Biomaterials 2014;35:133-142.
61. Seiler JP. Good Laboratory Practice-The Why and the How. New York: Springer-Verlag, 2005.
62. Millenium Research Group. US Peripheral Vascular Device Market to Grow Strongly to $3.3 Billion by 2017. Available at http: //mrg.net/News-and-Events/Press-Releases/ Peripheral-Vascular-Devices-012313.aspx. Accessed June 25, 2014.
63. Wood L. Research and Markets: Myocardial Infarction (MI) Therapeutics-Pipeline Assessment and Market Forecasts to 2018. Available at www.businesswire.com/news/ home/20120117006656/en/Research-Markets-Myocardial-Infarction-MI-Therapeutics-#.U6tE5 xYfKNA. Accessed June 25, 2014.